Details for Patent: 10,383,884

Which drugs does patent 10,383,884 protect, and when does it expire?

Patent 10,383,884 protects NUZYRA and is included in two NDAs.

This patent has fourteen patent family members in twelve countries.

Summary for Patent: 10,383,884

Title:	9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP)
Abstract:	The invention disclosed herein provides a method for treating Community-Acquired Bacterial Pneumonia (CABP) using 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, in either oral or IV doses or a combination of both.
Inventor(s):	Tzanis; Evangelos L. (Newtown Square, PA), McGovern; Paul (Berwyn, PA), Manley; Amy L. (Phoenixville, PA), Garrity-Ryan; Lynne (Melrose, MA), Tanaka; S. Ken (Bellevue, WA)
Assignee:	Paratek Pharmaceuticals, Inc. (Boston, MA)
Application Number:	15/798,573
Patent Claim Types: see list of patent claims	Use; Dosage form;

Drugs Protected by US Patent 10,383,884

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Paratek Pharms Inc	NUZYRA	omadacycline tosylate	POWDER;INTRAVENOUS	209817-001	Oct 2, 2018		RX	Yes	Yes						TREATMENT OF COMMUNITY ACQUIRED BACTERIAL PNEUMONIA
Paratek Pharms Inc	NUZYRA	omadacycline tosylate	TABLET;ORAL	209816-001	Oct 2, 2018		RX	Yes	Yes						TREATMENT OF COMMUNITY ACQUIRED BACTERIAL PNEUMONIA

International Family Members for US Patent 10,383,884

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2017353588
Brazil	112019008897
Canada	3042514
China	110087655
European Patent Office	3534908